Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 146.07 +0.28 (+0.19%) Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 542,714 Open 147.35 Bid (Size) 141.00 (1) Ask (Size) 152.48 (1) Prev. Close 145.79 Today's Range 145.04 - 150.27 52wk Range 143.50 - 218.88 Shares Outstanding 118,847,693 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News How Is The Market Feeling About Alnylam Pharmaceuticals? April 19, 2024 Via Benzinga Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results April 18, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Performance YTD -25.07% -25.07% 1 Month -3.95% -3.95% 3 Month -20.58% -20.58% 6 Month -9.83% -9.83% 1 Year -28.67% -28.67% More News Read More 10 Health Care Stocks With Whale Alerts In Today's Session April 09, 2024 Via Benzinga Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data April 08, 2024 Via Benzinga Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension April 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today April 02, 2024 Via Benzinga Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback March 28, 2024 Via Investor's Business Daily Exposures Product Safety 3 Biotech Stocks to Buy on the Dip: March 2024 March 27, 2024 Via InvestorPlace Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session March 20, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Earnings Scheduled For February 15, 2024 February 15, 2024 Via Benzinga Alnylam Pharmaceuticals's Earnings Outlook February 14, 2024 Via Benzinga Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years March 18, 2024 Via Benzinga Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio March 13, 2024 Via InvestorPlace Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease March 13, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates March 09, 2024 Via Talk Markets Exposures Product Safety Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges March 05, 2024 Via Benzinga Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives March 05, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire 10 Health Care Stocks Whale Activity In Today's Session February 29, 2024 Via Benzinga Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today February 28, 2024 Via Benzinga Alnylam to Webcast Presentations at Upcoming March Investor Conferences February 27, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. February 23, 2024 Via Investor's Business Daily Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know February 16, 2024 Via Benzinga Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday? February 15, 2024 Via Benzinga Exposures Product Safety Why Alnylam Pharmaceuticals Stock Is Sinking Today February 15, 2024 Via The Motley Fool Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity February 15, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
